Severe asthma: anti-IgE or anti-IL-5?

Figures & data

Table 1 Anti IgE treatment in severe asthma and clinical outcomes

Study	No. of patients	No. of patients treated with anti-IgE	Outcome
Bousquet et al. (24)	4,308	2,511	⇓Exacerbation 38% ⇓Hospital admissions 52% ⇓ER visits 47%
Humbert et al. (25)	419	419	⇓Exacerbation rate 26% ⇑ QoL ⇑ Morning PEF ⇓Symptom scores
Normansell et al. (26)			⇓Exacerbation ⇓Hospitalisation ⇓ICS daily dose
Abraham et al. (27)			⇓Exacerbation ⇓Hospitalisations ⇓ER visits ⇓OCS 30–66%
Busse et al. (28)	419	208	⇓Number of days with asthma symptoms 24.5% ⇓Exacerbations ⇑ Asthma control: omalizumab+lower doses of inhaled glucocorticoids (p <0.001) and LABA (p=0.003)
Hanania et al. (29)	850	427	⇓Mean daily albuterol puffs ⇓(−0.27 puff/day) ⇓Exacerbations ⇑ AQLQ(S) scores ⇓Asthma symptom score
Chen. et al. (30)			⇓Total ICS dose ⇓SABA ⇓LTRA

ER, emergency room; PEF, peak expiratory flow; ICS, inhaled corticosteroids; LABA, long acting beta2 agonists; AQLQ, Asthma Quality of Life Questionnaire; SABA, short acting beta2 agonists; LTRA, leukotriene receptor antagonists.

Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, etal. The effect of treatment with omalizumab, an anti-IgE antibody, in asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005; 60: 302–8.

 PubMed Web of Science ®Google Scholar

Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, etal. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60: 309–16.

 PubMed Web of Science ®Google Scholar

Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014; 003559.

 Google Scholar

Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy. 2016; 71: 593–610.

 PubMed Web of Science ®Google Scholar

Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, etal. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011; 364: 1005–15.

 PubMed Web of Science ®Google Scholar

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, etal. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011; 154: 573–82.

 PubMed Web of Science ®Google Scholar

Chen H, Eisner MD, Haselkorn T, Trzaskoma B. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respir Med. 2013; 107: 60–7.

 PubMed Web of Science ®Google Scholar